DE69628645D1 - Benzimidazolderivaten-enthaltende pharmazeutische zusammensetzungen zur inhibierung des krebswachstums - Google Patents

Benzimidazolderivaten-enthaltende pharmazeutische zusammensetzungen zur inhibierung des krebswachstums

Info

Publication number
DE69628645D1
DE69628645D1 DE69628645T DE69628645T DE69628645D1 DE 69628645 D1 DE69628645 D1 DE 69628645D1 DE 69628645 T DE69628645 T DE 69628645T DE 69628645 T DE69628645 T DE 69628645T DE 69628645 D1 DE69628645 D1 DE 69628645D1
Authority
DE
Germany
Prior art keywords
carbon atoms
less
hydrogen
pharmaceutical compositions
compositions containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69628645T
Other languages
English (en)
Other versions
DE69628645T2 (de
Inventor
Berger Camden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UAF Technologies and Research LLC
Original Assignee
University of Arizona Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Arizona Foundation filed Critical University of Arizona Foundation
Publication of DE69628645D1 publication Critical patent/DE69628645D1/de
Application granted granted Critical
Publication of DE69628645T2 publication Critical patent/DE69628645T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69628645T 1995-04-12 1996-04-11 Benzimidazolderivaten-enthaltende pharmazeutische zusammensetzungen zur inhibierung des krebswachstums Expired - Fee Related DE69628645T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US42091495A 1995-04-12 1995-04-12
US420914 1995-04-12
US47381795A 1995-06-07 1995-06-07
US473817 1995-06-07
US183795P 1995-08-03 1995-08-03
US1837 1995-08-03
PCT/US1996/004955 WO1996032107A1 (en) 1995-04-12 1996-04-11 A pharmaceutical composition containing benzimidazole for inhibiting the growth of cancers

Publications (2)

Publication Number Publication Date
DE69628645D1 true DE69628645D1 (de) 2003-07-17
DE69628645T2 DE69628645T2 (de) 2004-05-13

Family

ID=27357012

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69628645T Expired - Fee Related DE69628645T2 (de) 1995-04-12 1996-04-11 Benzimidazolderivaten-enthaltende pharmazeutische zusammensetzungen zur inhibierung des krebswachstums

Country Status (19)

Country Link
EP (1) EP0821586B1 (de)
JP (2) JPH11503459A (de)
KR (1) KR19980703828A (de)
CN (1) CN1181010A (de)
AT (1) ATE242634T1 (de)
AU (1) AU714078B2 (de)
BR (1) BR9604974A (de)
CA (1) CA2217952C (de)
CZ (1) CZ323497A3 (de)
DE (1) DE69628645T2 (de)
HU (1) HUP9801532A3 (de)
IL (1) IL117875A0 (de)
NO (1) NO974695L (de)
NZ (1) NZ305784A (de)
PL (1) PL322733A1 (de)
SK (1) SK138497A3 (de)
TR (2) TR199801562T2 (de)
TW (1) TW427887B (de)
WO (1) WO1996032107A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262093B1 (en) 1995-04-12 2001-07-17 The Proctor & Gamble Company Methods of treating cancer with benzimidazoles
US6177460B1 (en) 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
US6479526B1 (en) 1995-04-12 2002-11-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
US6265427B1 (en) 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
US5770616A (en) 1995-06-07 1998-06-23 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
CA2223435A1 (en) * 1995-06-07 1996-12-19 James Berger Camden Use of benzimidazoles for the manufacture of a medicament for the treatment of leukemia
US6686391B2 (en) 1995-08-04 2004-02-03 University Of Arizona Foundation N-chlorophenylcarbamate and N-chlorophenylthiocarbamate compositions
US5900429A (en) 1997-01-28 1999-05-04 The Procter & Gamble Company Method for inhibiting the growth of cancers
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
AU763272B2 (en) * 1997-05-16 2003-07-17 Uaf Technologies And Research Llc Benzimidazole-2-carbamates for the treatment of viral infections and cancer
US6245789B1 (en) 1998-05-19 2001-06-12 The Procter & Gamble Company HIV and viral treatment
PT2055313E (pt) * 1998-11-09 2015-08-25 Biogen Idec Inc Tratamento de malignidades hematológicas associadas a células tumorais em circulação utilizando anticorpo quimérico anti-cd20
US6423734B1 (en) 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer
US6384049B1 (en) * 2000-05-25 2002-05-07 The Procter & Gamble Company Cancer treatment
US6407105B1 (en) 2000-09-26 2002-06-18 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6462062B1 (en) 2000-09-26 2002-10-08 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6608096B1 (en) 2000-09-26 2003-08-19 University Of Arizona Foundation Compounds and methods for use thereof in the treatment of cancer or viral infections
US6380232B1 (en) 2000-09-26 2002-04-30 The Procter & Gamble Company Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof
WO2002041891A2 (en) * 2000-11-01 2002-05-30 The Procter & Gamble Company Hiv treatment with benzimidazoles
US6693125B2 (en) * 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
WO2003082273A1 (en) 2002-03-26 2003-10-09 Arizona Board Of Regents On Behalf Of The University Of Arizona Solubilization of weak bases
US20060153786A1 (en) 2004-12-10 2006-07-13 Talima Therapeutics, Inc. Compositions and methods for treating conditions of the nail unit
US20060275230A1 (en) 2004-12-10 2006-12-07 Frank Kochinke Compositions and methods for treating conditions of the nail unit
CN105377355A (zh) 2013-03-14 2016-03-02 拇趾公司 治疗甲单元的感染、疾病或病症的方法
CN103450093A (zh) * 2013-09-06 2013-12-18 中国药科大学 2-苄氨基苯并咪唑类化合物及其用途
CN108383797B (zh) * 2018-03-09 2020-07-21 浙江农林大学 一种防腐化合物及其制备方法与应用
US20240082294A1 (en) * 2021-01-06 2024-03-14 Florida Atlantic University Board Of Trustees Cancer treatment regimen using anti-parasitic compounds and gut microbiome modulating agents
KR102342313B1 (ko) * 2021-08-27 2021-12-24 (주)바이오메트릭스 테크놀로지 벤지미다졸-탄수화물 결합체 화합물을 포함하는 미셀, 이의 제조방법, 이의 항암제 또는 항바이러스제로서의 용도

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114951A (en) * 1989-04-11 1992-05-19 Burroughs Wellcome Company Agents for combating multiple drug resistance

Also Published As

Publication number Publication date
KR19980703828A (ko) 1998-12-05
WO1996032107A1 (en) 1996-10-17
HUP9801532A2 (hu) 1999-01-28
SK138497A3 (en) 1998-05-06
JP2007284446A (ja) 2007-11-01
CA2217952A1 (en) 1996-10-17
EP0821586B1 (de) 2003-06-11
IL117875A0 (en) 1996-08-04
EP0821586A1 (de) 1998-02-04
TR199701147T1 (xx) 1998-02-21
ATE242634T1 (de) 2003-06-15
TW427887B (en) 2001-04-01
TR199801562T2 (xx) 1998-10-21
JPH11503459A (ja) 1999-03-26
CZ323497A3 (cs) 1998-03-18
CN1181010A (zh) 1998-05-06
NO974695D0 (no) 1997-10-10
CA2217952C (en) 2002-06-25
BR9604974A (pt) 1998-06-09
PL322733A1 (en) 1998-02-16
NZ305784A (en) 2001-03-30
NO974695L (no) 1997-12-08
HUP9801532A3 (en) 1999-05-28
DE69628645T2 (de) 2004-05-13
AU714078B2 (en) 1999-12-16
AU5389796A (en) 1996-10-30

Similar Documents

Publication Publication Date Title
ATE242634T1 (de) Benzimidazolderivaten-enthaltende pharmazeutische zusammensetzungen zur inhibierung des krebswachstums
MX9707809A (es) Una composicion farmaceutica que contiene bencimidazol para inhibir el crecimiento de canceres.
NZ335013A (en) Compositions comprising cytosine derivatives for the treatment of cancer
IL104024A (en) 4-pyrimidinyl and pyridinyl derivatives of indol-3-yl- alkyl piperazines and antimigraine pharmaceutical compositions containing them
TR199900481T2 (xx) �ndazol t�revleri; fosfodiesteraz tip IV inhibit�rleri olarak kullan�mlar�.
ATE37179T1 (de) Dihydropyridazinone.
DE69923849D1 (de) Quinolin-2-on-derivate verwendbar als antikrebsmittel
IL148498A0 (en) Quinazoline derivatives
WO2002009716A3 (en) Use of an aldehyde 5-oxo-1,2,4-triazine hydrazide for the treatment of cancer
ATE279192T1 (de) Die verwendung eines benzimidazoles zur herstellung eines medikamentes zur krebsvorbeugung
NO20004162D0 (no) Antitumor agens
TW360652B (en) Acryloyl substituted disstamycin derivatives, process for preparing them, and pharmaceutical composition comprising them
TR200002466T2 (tr) Azetidin ve pirolidin türevleri
HUP0203422A2 (hu) Foszfodiészteráz VII inhibitor hatású imidazolszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP9900901A2 (hu) N-(Klór-fenil)-karbamátokat és N-(klór-fenil)-tiokarbamátokat tartalmazó, rákellenes és vírusok szaporodását gátló gyógyszerkészítmény
NO975660L (no) Anvendelse av benzimidazoler for fremstilling av et medikament for behandling av leukemi
DE69312567D1 (de) 2-Formylpyridin-Thiosemicarbazonderivate, ihre Herstellung und ihre Verwendung als Antitumor Mittel
ZA889023B (en) 2-(piperazinyl)-2-oxoethylene substituted flavonoid derivatives,processes for preparing them and pharmaceutical compositions containing them
SE8800863D0 (sv) 3-(2-haloethyl)-1,4-oxathiins and 2-(2-haloethyl)-1,4-dithiins and treatment of leukemia and tumors therewith
AP9901559A0 (en) Tricyclic 3-keto derivatives of 6-0-methylerythromycin.
MX9709833A (es) Uso de benzimidazoles para la fabricacion de un medicamento para el tratamiento de leucemia.
DK0760375T3 (da) Antitumor-indolopyrrolocarbazolderivater

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: UAF TECHNOLOGIES AND RESEARCH, LLC, TUCSON, ARIZ.,

8339 Ceased/non-payment of the annual fee